Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043966 · ClinicalTrials.gov registry record · Phase 3
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00043966 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 200 participants.
The verdict
NCT00043966, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavir/ritonavir.
Interventions
- DRUG Tenofovir DF
- DRUG Emtricitabine
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043966
The ClinicalTrials.gov registry entry for NCT00043966 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tenofovir DF is the first listed.
NCT00043966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043966 about?
NCT00043966 is a clinical study titled "Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects". The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavir/ritonavir.
What is the current status of trial NCT00043966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2002-07.
What interventions are being tested in trial NCT00043966?
The interventions under investigation include: Tenofovir DF (DRUG), Emtricitabine (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00043966?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.